Scarica l'app Stockscreener
7.86
4.94%
0.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.49
Aprire:
$7.58
Volume 24 ore:
443.75K
Relative Volume:
1.46
Capitalizzazione di mercato:
$443.57M
Reddito:
-
Utile/perdita netta:
$-72.89M
Rapporto P/E:
-3.2479
EPS:
-2.42
Flusso di cassa netto:
$-68.47M
1 W Prestazione:
+6.07%
1M Prestazione:
-12.08%
6M Prestazione:
-32.71%
1 anno Prestazione:
-39.68%
Intervallo 1D:
$7.51
$7.95
Intervallo di 1 settimana:
$7.34
$7.95
Portata 52W:
$7.16
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Nome
Astria Therapeutics Inc
Settore
Industria
Telefono
617-349-1971
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta ATXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
7.86 | 443.57M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-29 | Iniziato | TD Cowen | Buy |
| 2023-03-28 | Iniziato | Evercore ISI | Outperform |
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
Astria Therapeutics (NASDAQ:ATXS) Earns Outperform Rating from Analysts at JMP Securities - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Upgraded by Citizens Jmp to Strong-Buy Rating - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 25.7% in January - MarketBeat
Astria wins new Outperform rating at JMP on drug technology - MSN
Astria stock wins new Outperform at JMP (ATXS:NASDAQ) - Seeking Alpha
JMP Securities Initiates Astria Therapeutics at Outperform -January 31, 2025 at 08:17 am EST - Marketscreener.com
JMP Securities starts Astria Therapeutics stock with $26 target By Investing.com - Investing.com Canada
JMP Securities starts Astria Therapeutics stock at Market Outperform By Investing.com - Investing.com UK
JPMorgan Chase & Co. Increases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
What To Expect From Astria Therapeutics In Q4 - RTTNews
Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright sets $16 target on Astria Therapeutics stock - MSN
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
Astria Therapeutics Launches Phase 1a Trial of Novel Atopic Dermatitis Treatment STAR-0310 - StockTitan
Where are the Opportunities in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus Price Target from Brokerages - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Barclays PLC Has $1.02 Million Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics plans phase 3 trial for HAE drug - Investing.com
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Jane Street Group LLC Has $404,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Jane Street Group LLC Cuts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Astria Therapeutics Awards Stock Options to New Employees Under Inducement Plan - StockTitan
Geode Capital Management LLC Trims Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Geode Capital Management LLC Has $10.50 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Barclays PLC Boosts Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Decrease in Short Interest - MarketBeat
(ATXS) Investment Analysis - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 3.4%Here's What Happened - MarketBeat
State Street Corp Reduces Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
State Street Corp Sells 495,436 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.60 - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $613,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics expands stock incentive plan - Investing.com
Astria Therapeutics Expands Stock Incentive Plan - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus PT from Brokerages - MarketBeat
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6% - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $3.46 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria’s OX40 antagonist gains US IND clearance for atopic dermatitis - BioWorld Online
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire
FDA clears Astria Therapeutics' new AD drug for trial By Investing.com - Investing.com Canada
Astria's Navenibart Shows Remarkable 95% HAE Attack Reduction in Phase 1b/2 Trial Results - StockTitan
Astria Therapeutics Inc Azioni (ATXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Astria Therapeutics Inc Azioni (ATXS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):